Genentech Bets On Kineta's Early-Stage, Disease-Modifying Pain Therapy
Genentech partners with the Seattle biotech on a non-opioid approach to chronic pain. Kineta says there's disease-modifying potential.

Genentech partners with the Seattle biotech on a non-opioid approach to chronic pain. Kineta says there's disease-modifying potential.